Chemo-Free combo shows promise for older CLL patients

NCT ID NCT02315768

Completed Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a combination of two drugs, ibrutinib and obinutuzumab, in 32 older adults (65+) or those with health issues who had untreated chronic lymphocytic leukemia (CLL). The goal was to see if the combo could safely reduce cancer cells without using chemotherapy. The trial looked at side effects, dose limits, and how well the cancer responded.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ibrutinib and obinutuzumab (two drugs taken together)
What this could lead to: If successful, this combination could offer a chemotherapy-free treatment option for older or frail patients with chronic lymphocytic leukemia (CLL).
What could go wrong: This was an early-phase trial with only 32 participants, so results may not apply to everyone. Side effects from the drugs are possible, and long-term benefits are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

UCSD Moores Cancer Center

La Jolla, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.